The bottom line was boosted by an exceptional gain of ₹58 crore during the quarter, against none in the year-ago period. Previous Post Cipla to acquire 100% stake in Inzpera Healthsciences for ₹111 crore Next Post Gland Pharma Q2 net profit up 12% to ₹184 crore on higher revenue, R&D, new US launches Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Post Comment
